Craig-Hallum Sticks to Its Buy Rating for Inotiv (NOTV)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Inotiv (NOTV – Research Report). The company’s shares closed yesterday at $4.17.

Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, BioLife Solutions, and Apyx Medical. According to TipRanks, Hewitt has an average return of -2.8% and a 46.76% success rate on recommended stocks.

In addition to Craig-Hallum, Inotiv also received a Buy from Lake Street’s Frank Takkinen in a report issued today. However, yesterday, Jefferies downgraded Inotiv (NASDAQ: NOTV) to a Hold.

The company has a one-year high of $11.42 and a one-year low of $1.61. Currently, Inotiv has an average volume of 497.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inotiv (NOTV) Company Description:

Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.